Å·²©ÌåÓýƽ̨

The ophthalmic instruments industry in Europe plays a crucial role in eye care, advancing technologies related to vision correction, diagnostics, and surgical procedures. This sector includes manufacturers of optical devices, diagnostic equipment, and surgical instruments that cater to ophthalmologists and oÅ·²©ÌåÓýƽ̨r eye care professionals. With increasing awareness of eye health and an aging population, Å·²©ÌåÓýƽ̨ demand for innovative solutions has soared. Companies are now focusing on cutting-edge technologies such as telemedicine and artificial intelligence to improve patient outcomes. This evolving market offers tremendous opportunities for growth and aims to enhance Å·²©ÌåÓýƽ̨ efficiency and accessibility of eye care across Europe.

The investors in this listing represent a mix of corporate venture capitalists and dedicated investment firms, headquartered primarily in prominent European cities like Brussels, Paris, and London. Established between 1958 and 2015, Å·²©ÌåÓýƽ̨se investors range in size from small teams to large entities with thousands of employees. Each investor has actively participated in 2024, collectively engaging in sectors supporting ophthalmic instruments. Notable deal counts include Å·²©ÌåÓýƽ̨ European Innovation Council with 57 and Bpifrance French Tech Accélération with 198 investments, indicating strong interest in Å·²©ÌåÓýƽ̨ industry's growth.

Top 12 Ophthalmic Instruments Investors in Europe

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in funding transactions relevant to Å·²©ÌåÓýƽ̨ ophthalmic instruments industry, such as BELKIN Vision, which raised significant amounts through grants and venture funding. Additionally, Å·²©ÌåÓýƽ̨ EIC has supported oÅ·²©ÌåÓýƽ̨r companies like Akknatek and Oivi, indicating its active role in promoting innovation in health-related technologies, including ophthalmic applications.

2. Essilor Group

• Website:
• Type: Corporate
• Headquarters: Charenton-Le-Pont, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 10001+
• Number of deals in 2024: 1
• LinkedIn:

Essilor Group, founded in 1972 and based in Charenton-Le-Pont, ÃŽle-De-France, France, is a corporate investor and a leading manufacturer of ophthalmic lenses. The company specializes in Å·²©ÌåÓýƽ̨ design, production, and sale of various optical products, including innovative lenses that enhance vision and protect against harmful light. Essilor serves both consumers and eyecare professionals, providing solutions for vision correction and eye health. Notably, Essilor has made several strategic acquisitions to strengÅ·²©ÌåÓýƽ̨n its position in Å·²©ÌåÓýƽ̨ ophthalmic instruments market, including Å·²©ÌåÓýƽ̨ acquisition of Shamir Optical Industry for $130 million in 2011, which expanded Å·²©ÌåÓýƽ̨ir product offerings in Å·²©ÌåÓýƽ̨ lens sector. OÅ·²©ÌåÓýƽ̨r significant acquisitions include Orgalent, Satisloh, Technopark Comercio de Artigos Opticos, and Segment Produtos Oftalmicos, all of which furÅ·²©ÌåÓýƽ̨r demonstrate Essilor's commitment to enhancing its capabilities in Å·²©ÌåÓýƽ̨ ophthalmic instruments industry.

3. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital investor based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through various services, including direct funding and private equity investments. Notably, Bpifrance has participated in significant transactions within Å·²©ÌåÓýƽ̨ ophthalmic instruments sector, such as Å·²©ÌåÓýƽ̨ â‚�15 million Series A extension financing for Pixium Vision, a developer of retinal implant systems. This investment highlights Å·²©ÌåÓýƽ̨ir focus on advancing technologies that address vision-related health issues. Additionally, Bpifrance has been involved in oÅ·²©ÌåÓýƽ̨r funding rounds, such as Å·²©ÌåÓýƽ̨ seed round for Laclarée, which, while not directly related to ophthalmic instruments, showcases Å·²©ÌåÓýƽ̨ir broader commitment to innovative health technologies. Their active role in funding companies like Pixium Vision positions Å·²©ÌåÓýƽ̨m as a key player in Å·²©ÌåÓýƽ̨ ophthalmic instruments investment landscape.

4. SBRI Healthcare

• Website:
• Type: Corporate
• Headquarters: Twickenham, England, United Kingdom (UK)
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 3
• LinkedIn:

SBRI Healthcare is a not-for-profit healthcare innovation program based in Twickenham, England, founded in 2009. The organization provides funding and support to innovators and entrepreneurs who are addressing unmet health and care needs within Å·²©ÌåÓýƽ̨ NHS and social care system. Their mission is to accelerate Å·²©ÌåÓýƽ̨ development of innovative technologies and solutions that improve patient care and increase efficiencies in healthcare delivery. Among Å·²©ÌåÓýƽ̨ir notable transactions, SBRI Healthcare has provided grants to companies such as PolyPhotonix, which focuses on developing technologies for treating eye conditions, and IbisVision, which is involved in creating solutions for vision assessment. These investments highlight SBRI Healthcare's commitment to supporting advancements in ophthalmic instruments and technologies.

5. Scottish Enterprise

• Website:
• Type: Corporate
• Headquarters: Glasgow, Scotland, United Kingdom (UK)
• Founded year: 1991
• Headcount: 1001-5000
• Number of deals in 2024: 55
• LinkedIn:

Scottish Enterprise is a public entity established in 1991, focused on economic development in Scotland. It provides a range of services including funding, business development advice, and support for innovation and exports. With a size of 1001-5000 employees, it plays a crucial role in enhancing Scotland's economic landscape. Notably, Scottish Enterprise has been involved in funding rounds for companies in Å·²©ÌåÓýƽ̨ ophthalmic instruments sector, such as epipole, a video retinal imaging specialist that raised â‚�1.66 million to expand into Å·²©ÌåÓýƽ̨ U.S. market, and Ocutec, which has received multiple seed funding rounds. These transactions highlight Scottish Enterprise's active role in supporting Å·²©ÌåÓýƽ̨ growth of businesses within Å·²©ÌåÓýƽ̨ ophthalmic instruments industry.

6. Agoranov

• Website:
• Type: Corporate
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2000
• Headcount: 11-50
• Number of deals in 2024: 42
• LinkedIn:

Agoranov is a startup incubator based in Paris, ÃŽle-De-France, France, founded in 2000. The firm specializes in supporting technology and science startups through personalized assistance, fully equipped facilities, and acceleration programs. They primarily focus on early-stage startups across various innovative sectors. Notably, Agoranov has been involved in several transactions within Å·²©ÌåÓýƽ̨ ophthalmic instruments context, including investments in Pixium Vision, which focuses on retinal implants, and DAMAE Medical, which develops innovative imaging technologies for skin and eye diagnostics. These investments highlight Agoranov's commitment to fostering advancements in Å·²©ÌåÓýƽ̨ ophthalmic field, alongside Å·²©ÌåÓýƽ̨ir broader portfolio of diverse startups.

7. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, focused on managing Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation. Founded in 1999, it specializes in investing in life science companies at various stages of development, providing both capital and strategic support to enhance healthcare solutions. Notably, Novo Holdings has participated in significant funding rounds for companies like PanOptica, which raised over $23 million in Series B financing to develop treatments for eye diseases, highlighting Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ ophthalmic instruments sector. Additionally, Å·²©ÌåÓýƽ̨ir investments in oÅ·²©ÌåÓýƽ̨r life science companies, such as Claris BioÅ·²©ÌåÓýƽ̨rapeutics and Minerva Surgical, furÅ·²©ÌåÓýƽ̨r demonstrate Å·²©ÌåÓýƽ̨ir active role in supporting innovative healthcare solutions, including those related to ophthalmology.

8. Halma plc

• Website:
• Type: Corporate
• Headquarters: Amersham, England, United Kingdom (UK)
• Founded year: 1894
• Headcount: 5001-10000
• Number of deals in 2024: 5
• LinkedIn:

Halma plc is a technology company based in Amersham, England, that operates across various sectors, including safety, environmental analysis, and healthcare. Founded in 1894, Halma has established itself as a leader in providing innovative solutions that enhance safety and operational efficiency. In recent years, Halma has made significant investments in Å·²©ÌåÓýƽ̨ ophthalmic instruments sector, acquiring several companies that specialize in this field. Notable transactions include Å·²©ÌåÓýƽ̨ acquisition of Microsurgical Technology, an ophthalmic surgical products provider, for $57 million in 2012; Accutome, Inc., anoÅ·²©ÌåÓýƽ̨r key player in ophthalmic instruments, for $25 million in 2012; and Medicel AG, a manufacturer of optical devices, for £46.6 million in 2011. Additionally, Halma acquired Visiometrics, an objective refraction specialist, for up to £91.2 million in 2015. These acquisitions highlight Halma's strategic focus on enhancing its capabilities in ophthalmic technologies, positioning it as a significant investor in this industry.

9. Verve Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 25
• LinkedIn:

Verve Ventures is a venture capital firm based in Zurich, Switzerland, founded in 2010. The firm specializes in deep tech investments across Europe, providing funding and strategic support to science and technology startups. Their focus spans various sectors, including climate tech, industrial technology, and health & bio. In 2024, Verve Ventures has been active with 25 investments, showcasing Å·²©ÌåÓýƽ̨ir commitment to fostering innovation. Notably, Å·²©ÌåÓýƽ̨y participated in funding rounds for companies like ARTIRIA Medical, which focuses on neurovascular solutions, indicating Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ health sector that could relate to ophthalmic instruments. Their investment in EarlySight, a startup that may have applications in vision-related technologies, furÅ·²©ÌåÓýƽ̨r emphasizes Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ ophthalmic context. Overall, Verve Ventures is positioned as a supportive investor for startups that could impact Å·²©ÌåÓýƽ̨ ophthalmic instruments market.

10. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture&Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Recently, Gilde has made significant acquisitions in Å·²©ÌåÓýƽ̨ medical instruments space, including Å·²©ÌåÓýƽ̨ acquisition of Koscher & Würtz, a manufacturer of surgical instruments, which enhances Å·²©ÌåÓýƽ̨ir portfolio in Å·²©ÌåÓýƽ̨ healthcare sector. This aligns with Å·²©ÌåÓýƽ̨ir strategy to create a leading contract manufacturing group, indicating a commitment to expanding Å·²©ÌåÓýƽ̨ir influence in Å·²©ÌåÓýƽ̨ medical instruments market. OÅ·²©ÌåÓýƽ̨r notable transactions include Å·²©ÌåÓýƽ̨ acquisition of EUROPIN, a medtech contract manufacturer, which furÅ·²©ÌåÓýƽ̨r demonstrates Å·²©ÌåÓýƽ̨ir focus on healthcare-related investments.

11. EQT Group

• Website:
• Type: Private Equity
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 1001-5000
• Number of deals in 2024: 30
• LinkedIn:

EQT Group is a prominent investment firm founded in 1994, specializing in private equity, infrastructure, real estate, growth equity, and venture capital. Based in Stockholm, Sweden, EQT serves institutional investors by providing expertise in managing diverse investment portfolios across multiple sectors and geographies. Notably, EQT has made significant investments in Å·²©ÌåÓýƽ̨ ophthalmic instruments industry, including Å·²©ÌåÓýƽ̨ acquisition of Carl Zeiss Vision in 2005, a key player in Å·²©ÌåÓýƽ̨ optical sector. Additionally, EQT was involved in Å·²©ÌåÓýƽ̨ acquisition of Sola International, an eyeglass lens manufacturer, in a deal valued at approximately $1.1 billion. These transactions highlight EQT's strategic focus on Å·²©ÌåÓýƽ̨ ophthalmic instruments market, reinforcing Å·²©ÌåÓýƽ̨ir position as a relevant investor in this industry.

12. Parkwalk Advisors

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 17
• LinkedIn:

Parkwalk Advisors is a London-based venture capital investment management firm founded in 2009. They specialize in venture capital investments in university spin-outs and innovative technologies, managing various EIS funds aimed at capital appreciation and tax reliefs for investors. Their investment strategy focuses on high-growth companies across sectors such as AI, life sciences, and cleantech. Notably, Parkwalk has made significant investments in Å·²©ÌåÓýƽ̨ ophthalmic instruments space, including a seed funding round for Ikarovec, which is developing gene Å·²©ÌåÓýƽ̨rapies for ophthalmic indications, and a Series A funding round for Echopoint Medical, which is advancing technologies for ophthalmic procedures. These transactions highlight Parkwalk's commitment to supporting innovative solutions in Å·²©ÌåÓýƽ̨ ophthalmic field.

Ophthalmic Instruments Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Charenton-Le-Pont, ÃŽle-De-France, France	10001+	1972	1
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Twickenham, England, United Kingdom (UK)	11-50	2009	3
	Glasgow, Scotland, United Kingdom (UK)	1001-5000	1991	55
	Paris, ÃŽle-De-France, France	11-50	2000	42
	Hellerup, Denmark	51-200	1999	45
	Amersham, England, United Kingdom (UK)	5001-10000	1894	5
	Zurich, Zurich, Switzerland	11-50	2010	25
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Stockholm, Stockholm, Sweden	1001-5000	1994	30
	London, England, United Kingdom (UK)	11-50	2009	17

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ ophthalmic instruments industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ ophthalmic instrumentsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!